Core Insights - The Chilean government announced the results of the 2026 global tender for flu vaccines, with Sinovac becoming the exclusive supplier, securing orders exceeding 8 million doses [1] - This marks the second consecutive year that Sinovac has been the sole supplier for Chile's flu vaccine needs, indicating the recognition of Sinovac's product quality and international fulfillment capabilities by the country's public health system [1] - In 2025, Sinovac's flu vaccines administered in Chile exceeded 8.3 million doses, achieving approximately 80% coverage of the target population, which laid a solid foundation for the renewal of the contract [1] Group 1 - The first batch of vaccines is expected to arrive in Chile by the end of January 2026, meeting the country's flu season protection needs [1] - Sinovac's collaboration with various partners in Chile has expanded from product supply to research collaboration and evidence building [1] - A multi-center clinical study on the quadrivalent flu vaccine, co-conducted by Sinovac and research partners from Chile and other countries, was published in the journal "Vaccines," confirming the vaccine's good immunogenicity and safety [1] Group 2 - Sinovac's flu vaccine has shown higher antibody titers against four types of influenza viruses compared to foreign control vaccines [1] - A Phase III study evaluating both humoral and cellular immune responses in the adult population in Chile was published in "Nature Communications," further demonstrating the scientific basis for the vaccine's good immunogenicity and safety [1] - Sinovac's flu vaccine continues to expand its global application, having entered nearly 20 countries and regions, with a cumulative supply of over 120 million doses, providing stable support for global flu prevention [2]